Chronic lymphocytic leukaemia vaccine - MaxCyteAlternative Names: Gene modified autologous B-CLL cell therapy - Maxcyte
Latest Information Update: 21 Sep 2015
At a glance
- Originator MaxCyte
- Developer Baylor College of Medicine
- Class Cancer vaccines
- Mechanism of Action CD40 ligand stimulants; Immunostimulants; Interleukin-2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia